Is it time to definitely abandon neuroprotection in acute ischemic stroke?
Sacchetti
Maria Luisa
ML
D000208:Acute Disease / Q000628:therapy; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000592:standards / Q000706:statistics & numerical data; D019610:Cytoprotection / Q000187:drug effects*; D004338:Drug Combinations; D004632:Emergency Medical Services / Q000592:standards; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D004338:Drug Combinations; D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents